GH
Guardant Health Inc.
Price performance
Sep 18, 2026About
Company activity
32 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 07/30 | GH | 8-K | Guardant Health Reports Strong Q2 2026 Results and Raises Revenue Guidance | — | — | — |
| 06/18 | GH | 8-K | Guardant Health Announces Election of Directors and Auditor Ratification at Annual Meeting | — | — | — |
| 05/07 | GH | 8-K | Guardant Health Reports 48% Revenue Growth and Raises 2026 Guidance | — | — | — |
| 04/27 | GH | 8-K | Guardant Health Announces Resignation of Chief Medical Officer | — | — | — |
| 02/19 | GH | 8-K | Guardant Health Reports 39% Revenue Growth for 2025 and Outlook for 2026 | — | — | — |
| 01/12 | GH | 8-K | Guardant Health Announces Strong Revenue Growth for 2025 | — | — | — |
| 11/07/25 | GH | 8-K | Guardant Health Announces Upsized Public Offering and Convertible Notes Offering | — | — | — |
| 10/29/25 | GH | 8-K | Guardant Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance | — | — | — |
| 09/24/25 | GH | 8-K | Guardant Health to Host Investor Day on September 24, 2025 | — | — | — |
| 09/15/25 | GH | 8-K | Guardant Health Appoints Former HHS Secretary Alex M. Azar II to Board of Directors | — | — | — |
| 07/30/25 | GH | 8-K | Guardant Health Reports Strong Q2 2025 Results and Raises Annual Revenue Guidance | — | — | — |
| 06/20/25 | GH | 8-K | Guardant Health, Inc. Announces Results of Annual Stockholder Meeting | — | — | — |
| 04/30/25 | GH | 8-K | Guardant Health Reports Strong Q1 2025 Financial Results and Raises Revenue Guidance | — | — | — |
| 04/09/25 | GH | 8-K | Guardant Health Extends Lease Agreement | — | — | — |
| 02/20/25 | GH | 8-K | Guardant Health Reports Strong 2024 Revenue Growth and Provides 2025 Outlook | — | — | — |
| 02/14/25 | GH | 8-K | Guardant Health, Inc. Exchanges New Convertible Senior Notes for Existing Notes | — | — | — |
| 02/07/25 | GH | 8-K | Guardant Health Announces Debt Exchange and New Notes Issuance | — | — | — |
| 01/13/25 | GH | 8-K | Guardant Health Announces Preliminary 2024 Financial Results and Regulation FD Disclosure | — | — | — |
| 11/06/24 | GH | 8-K | Guardant Health Reports 34% Revenue Growth in Q3 2024 and Raises Annual Guidance | — | — | — |
| 10/24/24 | GH | 8-K | Roberto A. Mignone Joins Guardant Health Board of Directors | — | — | — |
| 08/23/24 | GH | 8-K | Guardant Health Announces Open Market Sale Agreement Up to $400 Million | — | — | — |
| 08/07/24 | GH | 8-K | Guardant Health Reports Strong Q2 2024 Results and Raises Revenue Guidance | — | — | — |
| 07/29/24 | GH | 8-K | Guardant Health's Shield Blood Test Approved by FDA for CRC Screening | — | — | — |
| 07/18/24 | GH | 8-K | Guardant Health Appoints Dr. Manuel Hidalgo Medina to Board of Directors | — | — | — |
| 06/14/24 | GH | 8-K | Guardant Health Announces Results of Annual Meeting | — | — | — |
| 05/31/24 | GH | 8-K | Guardant Health Amends Executive Severance Plan | — | — | — |
| 05/24/24 | GH | 8-K | FDA Advisory Committee Strongly Recommends Approval of Guardant Health's Shield Blood Test for Colorectal Cancer Screening | — | — | — |
| 05/09/24 | GH | 8-K | Guardant Health Announces 31% Revenue Growth and Raises 2024 Guidance | — | — | — |
| 03/22/24 | GH | 8-K | Guardant Health Amends CEO Compensation Agreements | — | — | — |
| 02/22/24 | GH | 8-K | Guardant Health Reports 2023 Financial Results and Provides 2024 Outlook | — | — | — |
| 02/01/24 | GH | 8-K | Guardant Health Board Member Resigns | — | — | — |
| 01/08/24 | GH | 8-K | Guardant Health Announces Preliminary 2023 Financial Results | — | — | — |
GH filing record
Guardant Health Inc. (GH): 32 8-K filings summarized, the most recent on Jul 30, 2026.
What the 8-K filings said
- Jul 30, 2026 · high impact
Guardant Health, Inc. reported a 44% increase in second-quarter 2026 revenue to $335.0 million, driven by strong performance in Oncology and Screening. The company raised its 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%. Oncology revenue grew 38% to $219.1 million, while Screening…
Guardant Health Reports Strong Q2 2026 Results and Raises Revenue Guidance - Jun 18, 2026 · medium impact
Guardant Health, Inc. held its annual meeting of stockholders on June 17, 2026. All nominees for director were elected, and the selection of Deloitte & Touche LLP as the independent auditor was ratified. However, the proposal to approve the compensation of named executive officers was not approved, and the frequency…
Guardant Health Announces Election of Directors and Auditor Ratification at Annual Meeting - May 7, 2026 · high impact
Guardant Health, Inc. reported a 48% year-over-year increase in total revenue for the first quarter of 2026, reaching $301.7 million. The company attributed the growth to strong performance in its Oncology and Screening segments. Oncology revenue grew 36% to $205.0 million, while Screening revenue surged over 600% to…
Guardant Health Reports 48% Revenue Growth and Raises 2026 Guidance - Apr 27, 2026 · high impact
On April 27, 2026, Guardant Health, Inc. announced the resignation of Craig Eagle, M.D., its Chief Medical Officer, effective May 8, 2026. This marks a significant executive change for the company.
Guardant Health Announces Resignation of Chief Medical Officer - Feb 19, 2026 · medium impact
Guardant Health, Inc. reported a 39% increase in fourth quarter revenue for 2025, reaching $281.3 million, and a 33% increase for the full year 2025, reaching $982.0 million. The company expects revenue growth in the range of 27% to 30% for 2026. Key highlights include strong performance in oncology and screening…
Guardant Health Reports 39% Revenue Growth for 2025 and Outlook for 2026
SEC filings in the last five years
- 59 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K